FDA Approves First SGLT2 Inhibitor For Diabetes

The FDA said today that it had approved canaglifozin (Invokana, Johnson & Johnson), the first of a new class of diabetes drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Canaglifozin is indicated to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. The drug has been studied as monotherapy and in combination with other common treatments for type 2 diabetes including metformin, sulfonylurea, pioglitazone, and insulin.

Click here to read the full post on Forbes.

English: Logo of the .

Trackbacks

  1. […] FDA Approves First SGLT2 Inhibitor For Diabetes (cardiobrief.org) […]

Leave a Reply

%d bloggers like this: